(Total Views: 583)
Posted On: 09/01/2020 2:46:29 AM
Post# of 154119
Last Post Regarding Who Questions Who at the Type A "By Letter" FDA Meeting of September 4:
This is the relevant portion of CytoDyn's Press Release on the topic:
"The FDA has agreed to respond to the Company’s questions by September 4, 2020 concerning the additional information the FDA requires to resubmit the Biologics License Application (BLA) for leronlimab as a combination therapy for HIV."
Note that it says that the "FDA has agreed to respond to the Company's questions."
Please stop saying that CytoDyn is responding to the FDA's questions, they are not!
This is the relevant portion of CytoDyn's Press Release on the topic:
"The FDA has agreed to respond to the Company’s questions by September 4, 2020 concerning the additional information the FDA requires to resubmit the Biologics License Application (BLA) for leronlimab as a combination therapy for HIV."
Note that it says that the "FDA has agreed to respond to the Company's questions."
Please stop saying that CytoDyn is responding to the FDA's questions, they are not!
(4)
(0)
